Evidence map›Paper›PMID 37548746›Full record

ArticleWorld journal of urology2023

5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data.

Francesco Del Giudice, Federico Belladelli, Frank Glover, Satvir Basran, Shufeng Li, Evan Mulloy, Benjamin Pradere, Francesco Soria, Wojciech Krajewski, Rajesh Nair and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 6 countries.

Francesco Del GiudiceDepartment of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, Rome, Italy. francesco.delgiudice@uniroma1.it.ORCID http://orcid.org/0000-0003-3865-5988
Federico BelladelliDepartment of Urology, Stanford University School of Medicine, Stanford, CA, USA.
Frank GloverGangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Satvir BasranDepartment of Urology, Stanford University School of Medicine, Stanford, CA, USA.
Shufeng LiDepartment of Urology, Stanford University School of Medicine, Stanford, CA, USA.
Evan MulloyDepartment of Urology, Stanford University School of Medicine, Stanford, CA, USA.
Benjamin PradereDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1030, Vienna, Austria.
Francesco SoriaUrology Division, Department of Surgical Sciences, University of Studies of Torino, 10124, Turin, Italy.
Wojciech KrajewskiDepartment of Minimally Invasive and Robotic Urology, Wrocław Medical University, 50-367, Wrocław, Poland.
Rajesh NairDepartment of Urology, Guys and St, Thomas' NHS Foundation Trust, London, England.
Wade MunceyDepartment of Urology, Stanford University School of Medicine, Stanford, CA, USA.
Nicolas SeranioDepartment of Urology, Stanford University School of Medicine, Stanford, CA, USA.
Michael L EisenbergDepartment of Urology, Stanford University School of Medicine, Stanford, CA, USA.
Stanford University · USComprehensive Cancer Center Vienna · ATEmory University · USGuy's and St Thomas' NHS Foundation Trust · GBPoliclinico Umberto I · ITUniversity of Turin · ITVita-Salute San Raffaele University · ITWroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChemoprotective effect of 5-alpha reductase inhibitors (5-ARi) on bladder cancer (BCa) risk in men with Benign Prostatic Hyperplasia (BPH) has been explored with conflicting results. We sought to examine the effect of 5-ARi on new BCa diagnoses in a large US database.

methodsMen ≥ 50 y/o with a prescription for 5-ARi after BPH diagnosis were identified in the IBM® Marketscan® Research de-identified Databases between 2007 and 2016 and matched with paired controls. Incident BCa diagnoses were identified after BPH diagnosis and/or pharmacologic treatment. Multivariable regression modeling adjusting for relevant factors was implemented. Sub-group analyses by exposure risk were performed to explore the association between 5-ARi and BCa over time. Administration of alpha-blockers (α-B) w/o 5-ARi was also examined.

resultsIn total, n = 24,036 men on 5-ARi, n = 107,086 on 5-ARi plus alpha-blockers, and n = 894,275 without medical therapy for BPH were identified. The percentage of men diagnosed with BCa was 0.8% for the 5-ARi, 1.4% for the 5-ARi + α-B, and 0.6% for the untreated BPH group of incident BCa (adjusted hazard ratio [aHR], 0.90, 95% confidence interval [CI] 0.56 - 1.47), and 1.08, 95%CI 0.89 - 1.30, respectively). This was also true at both shorter (≤ 2 yr) and longer-term (> 2 yr) follow up. In addition, α-B alone had no change in BCa risk (HR 1.06, 0.86-1.30).

conclusionsWe did not find any diminished risk of new BCa in men treated with 5-ARi (i.e., chemoprotective effect). The current report suggests that 5-ARi do not change a man's bladder cancer risk.

Indexed as

InsuranceProstatic HyperplasiaUrinary Bladder Neoplasms5-alpha Reductase InhibitorsHumansMaleRiskUnited States5-alpha Reductase Inhibitors5-alpha reductase inhibitor (5-ARi)Alpha blockersBenign prostatic hyperplasiaBladder cancer

Identifiers

PMID37548746
PMCPMC10582125
OpenAlexW4385616616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.